Advertisement

Organisation › Details
Oncimmune Ltd.
Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune is working to change how cancer is diagnosed and treated. Its patented technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune's tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. Oncimmune partners with leading developers and distributors to make our technology available globally. Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT-Lung and EarlyCDT-Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT-Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune, headquartered in Nottingham, UK has a CLIA lab in Kansas, US and offices in London, UK and Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L. *
![]() |
Start | 2002-01-01 splitoff |
Group | Freenome (Group) | |
Predecessor | University of Nottingham | |
![]() |
Industry | EarlyCDT® platform technology |
Industry 2 | EarlyCDT®-Lung test (CLIA test) | |
![]() |
Region | Nottingham, Nottinghamshire |
Country | United Kingdom (GB) | |
Street | 1 Thane Road MediCity Nottingham, D6 Building | |
City | NG90 6BH Nottingham | |
Tel | +44-1157-840-500 | |
Address record changed: 2023-06-27 | ||
Basic data | Employees | n. a. |
Currency | GBP | |
Annual sales | 1,345,000 (revenue (2014/15) 2015-05-31) | |
Profit | -2,013,000 (2015-05-31) | |
* Document for »About Section«: Oncimmune Holdings plc. (3/19/19). "Press Release: Oncimmune Announces the Acquisition of Protagen Diagnostics AG, a Leader in Personalised Immuno-Profiling". Cambridge, MA. | ||
Record changed: 2023-07-10 |
Advertisement

More documents for Freenome (Group)
- [1] Freenome, Inc.. (2/15/24). "Press Release: Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection". South San Francisco, CA....
- [2] Freenome, Inc.. (5/22/23). "Press Release: Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd". South San Francisco, CA....
- [3] Freenome, Inc.. (12/7/21). "Press Release: Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection". South San Francisco, CA....
- [4] Freenome, Inc.. (12/1/21). "Press Release: Freenome Partners with Siemens Healthineers for Breast Cancer Research". South San Francisco, CA....
- [5] Biognosys AG. (11/9/21). "Press Release: Biognosys Launches Next-Generation Blood Biomarker Discovery Solution". Schlieren....
- [6] Freenome, Inc.. (8/26/20). "Press Release: Freenome Closes $270 Million Series C Financing to Advance Novel Multiomics Blood Testing Platform for Early Cancer Detection". South San Francisco, CA....
- [7] Oncimmune Holdings plc. (9/20/19). "Press Release: €8.5m Credit Facility Secured. Funding to Accelerate the Further Commercialisation of Oncimmune’s Lead Products and Services"....
- [8] ADC Therapeutics S.A.. (8/26/19). "Press Release: ADC Therapeutics and Freenome Enter Biomarker Development Collaboration". Lausanne & South San Francisco, CA....
- [9] Freenome, Inc.. (7/24/19). "Press Release: Freenome Closes $160 Million Series B Financing to Advance Its Multiomics Blood Testing Platform for Early Cancer Detection". South San Francisco, CA....
- [10] Oncimmune Holdings plc. (6/28/19). "Press Release: Oncimmune Secures Strategic Commercialisation Agreement for EarlyCDT Lung in the US with Biodesix, Inc.". London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top